New York-based Taconic Biosciences, which specializes in genetically engineered rodent models and services, said it signed a license agreement with ERS Genomics to utilize the company’s CRISPR-Cas9 technology to generate “unique murine models.”
Under the agreement, Taconic receives a worldwide non-exclusive license to the CRISPR-Cas9 patents often referred to as the “UC Berkeley patent.”
Taconic said ERS Genomics founder Emmanuelle Charpentier is a co-inventor of the CRISPR-Cas9 technology.
Taconic said the agreement with ERS complements Taconic’s CRISPR service platform, adding to its existing license with the Broad Institute.
Holding licenses with both groups provides Taconic access for use in all cell types as well as for use in both mouse and rat species, a rare distinction within the animal model field, Taconic said.
“There is no doubt that CRISPR-Cas9 has revolutionized gene editing and thus drug discovery,” said John Couse, Taconic Biosciences’ director of genetically modified model design.
“Adding the ERS technology to Taconic’s existing CRISPR platform allows the company to stand out among competitors by offering a fully-licensed, comprehensive CRISPR platform.”